Gri Bio Inc. has announced new data from its recently completed Phase 2a clinical study of GRI-0621 in patients with Idiopathic Pulmonary Fibrosis (IPF). The results, which have already been presented, indicate that GRI-0621 met its primary endpoint by demonstrating favorable safety and tolerability. The study also met multiple secondary endpoints indicative of disease-modifying activity, and exploratory data showed that twice as many GRI-0621-treated subjects experienced no decline in forced vital capacity at 12 weeks compared to standard of care alone. Newly reported gene expression analysis revealed significant improvements in genes associated with lung injury, fibrosis progression, and tissue repair among treated subjects compared to placebo. These findings suggest a direct impact of GRI-0621 on the underlying biology of IPF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9643824-en) on January 28, 2026, and is solely responsible for the information contained therein.